1. Home
  2. RDHL vs XTIA Comparison

RDHL vs XTIA Comparison

Compare RDHL & XTIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • XTIA
  • Stock Information
  • Founded
  • RDHL 2009
  • XTIA 1999
  • Country
  • RDHL Israel
  • XTIA United States
  • Employees
  • RDHL N/A
  • XTIA N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • XTIA
  • Sector
  • RDHL Health Care
  • XTIA
  • Exchange
  • RDHL Nasdaq
  • XTIA NYSE
  • Market Cap
  • RDHL 4.3M
  • XTIA 10.6M
  • IPO Year
  • RDHL N/A
  • XTIA N/A
  • Fundamental
  • Price
  • RDHL $2.10
  • XTIA $2.03
  • Analyst Decision
  • RDHL
  • XTIA
  • Analyst Count
  • RDHL 0
  • XTIA 0
  • Target Price
  • RDHL N/A
  • XTIA N/A
  • AVG Volume (30 Days)
  • RDHL 18.8K
  • XTIA 7.9M
  • Earning Date
  • RDHL 08-28-2025
  • XTIA 08-13-2025
  • Dividend Yield
  • RDHL N/A
  • XTIA N/A
  • EPS Growth
  • RDHL N/A
  • XTIA N/A
  • EPS
  • RDHL N/A
  • XTIA N/A
  • Revenue
  • RDHL $8,042,999.00
  • XTIA $3,466,000.00
  • Revenue This Year
  • RDHL $381.91
  • XTIA $59.74
  • Revenue Next Year
  • RDHL N/A
  • XTIA N/A
  • P/E Ratio
  • RDHL N/A
  • XTIA N/A
  • Revenue Growth
  • RDHL 23.17
  • XTIA 1475.45
  • 52 Week Low
  • RDHL $1.71
  • XTIA $0.96
  • 52 Week High
  • RDHL $20.28
  • XTIA $101.78
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 61.27
  • XTIA 48.39
  • Support Level
  • RDHL $2.00
  • XTIA $1.68
  • Resistance Level
  • RDHL $2.08
  • XTIA $1.81
  • Average True Range (ATR)
  • RDHL 0.09
  • XTIA 0.22
  • MACD
  • RDHL 0.03
  • XTIA -0.10
  • Stochastic Oscillator
  • RDHL 100.00
  • XTIA 24.12

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About XTIA XTI AEROSPACE

XTI Aerospace Inc is an aircraft development company. It also provides real-time location systems (RTLS) for the industrial sector. The company is developing a vertical takeoff and landing (VTOL) airplane that is designed to take off and land like a helicopter and cruise like a fixed-wing business airplane. Its initial configuration, the TriFan 600 airplane, will be one of the first civilian fixed-wing VTOL airplane that offers the speed and comfort of a business airplane and the range and versatility of VTOL for a wide range of customer applications, including private aviation for business and high net worth individuals, emergency medical services, and regional charter air travel. The company operates in two reportable segments: Industrial IoT and Commercial Aviation.

Share on Social Networks: